GPR35 and ulcerative colitis: There has been growing interest in targeting GPR35 in a therapeutic context based, at least in part, on strong genetic association between single nucleotide polymorphic variants of human GPR35 and inflammatory diseases of the lower gut, including ulcerative colitis (2), as well as the high level of expression of the receptor in the colon and other regions of the intestine (2).